REG - N4 Pharma PLC - Holding(s) in Company

N4 PharmaAnnouncement

16/03/2020 10:30

RNS Number : 2637G
  
N4 Pharma PLC
  
16 March 2020
  
 

16 March 2020
 
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
 
Holding in Company
 
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has been notified today that, as of 26 July 2019, First Equity Limited no longer had a notifiable interest in the issued share capital of the Company.
 
Enquiries:
 



N4 Pharma Plc
Nigel Theobald, CEO
 


 
Via Scott PR




Allenby Capital Limited
James Reeve/Asha Chotai
 


Tel: +44(0)203 328 5656




Scott PR
Georgia Smith
 


Tel: +44(0)1477 539 539



 
About N4 Pharma
 
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
 
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
HOLFLFFIVFIRLII